TCRX supply chain intelligence for TScan Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
TScan Therapeutics, Inc. (TCRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| THE-BRIGHAM-AND-WOMEN-S-HOSPITAL-INC | THE-BRIGHAM-AND-WOMEN-S-HOSPITAL-INC | 90% | we obtained an exclusive, sublicensable, worldwide license to practice under certain of BWH's patent rights for identifying T cell epitopes, which are relevant to our target discovery platform for id… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from ALLO g… |
| ALLO | Allogene Therapeutics, Inc. | 72% | ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectively inserts our TCRs and other exogenous ge… |
| AUTL | Autolus Therapeutics plc | 72% | ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectively inserts our TCRs and other exogenous ge… |
| AUTL | Autolus Therapeutics plc | 72% | Reciprocal relationship from AUTL graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from AUTL graph: Reciprocal relationship from TCRX graph: ding transposase enzyme, which is d… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | Reciprocal relationship from IOVA graph: Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectively inserts our TCRs and other exogenous ge… |
| IPSC | Century Therapeutics, Inc. | 72% | ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectively inserts our TCRs and other exogenous ge… |
| IPSC | Century Therapeutics, Inc. | 72% | Reciprocal relationship from IPSC graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from IPSC g… |
| LEGN | Legend Biotech Corporation | 72% | ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectively inserts our TCRs and other exogenous ge… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from LEGN g… |
| LYEL | Lyell Immunopharma, Inc. | 72% | ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectively inserts our TCRs and other exogenous ge… |
| LYEL | Lyell Immunopharma, Inc. | 72% | Reciprocal relationship from LYEL graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from LYEL graph: Reciprocal relationship from TCRX graph: ding transposase enzyme, which is d… |
| MRKR | Marker Therapeutics, Inc. | 72% | Reciprocal relationship from MRKR graph: Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our… |
| MRKR | Marker Therapeutics, Inc. | 72% | ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectively inserts our TCRs and other exogenous ge… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from TCRX graph: ake estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our… |
| NVSEF | Novartis AG | 72% | ake estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other fact… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from TCRX graph: ding transposase enzyme, which is d… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectively inserts our TCRs and other exogenous ge… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AMGEN-INC | AMGEN-INC | 92% | Amgen made an upfront payment of $30.0 million to us, and we are eligible to earn success-based milestone payments of over $500 million based upon the achievement of certain development and commercia… |
| AMGN | Amgen Inc. | 92% | Reciprocal relationship from AMGN graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from TCRX graph: The Company concluded that Amgen me… |
| AMGN | Amgen Inc. | 92% | The Company concluded that Amgen meets the definition of a customer, as the Company is delivering research and development activities and a license of intellectual property. |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from TCRX graph: at a commercially reasonable cost or in a timely manner. In addition, we do not intend to pursue, and may not obtain,… |
| MYGN | Myriad Genetics, Inc. | 72% | at a commercially reasonable cost or in a timely manner. In addition, we do not intend to pursue, and may not obtain, patent protection in all potentially relevant markets. It is possible that we wil… |
| NVSEF | Novartis AG | 72% | ver $ million, based upon the achievement of certain clinical development and commercial milestones, as well as tiered single-digit royalty payments on net sales of products developed from the collab… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from NVSE… |
| CAPITAL-RESOURCES | CAPITAL-RESOURCES | 62% | es for the three months ended March 31, 2026 and 2025 (in thousands): Three Months Ended March 31, 2026 2025 Change Personnel expenses $ 3,517 $ 3,019 $ 498 Legal and professional fees 1,692 1,954 (2… |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | ddition, we have employed and expect to continue to employ individuals who were previously employed at university or other biotechnology or pharmaceutical companies, including our competitors or pote… |
| K-EMERGING-GROWTH-COMPANY | K-EMERGING-GROWTH-COMPANY | 62% | (ii) above. We also use judgment to determine whether milestones or other variable consideration, except for royalties and sales-based milestones, should be included in the transaction price as descr… |
| WEDBUSH-SECURITIES-INC | WEDBUSH-SECURITIES-INC | 62% | ovements to Income Tax Disclosures.” This ASU updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disag… |
| WOMEN-S-HOSPITAL-INC | WOMEN-S-HOSPITAL-INC | 62% | e passed laws that regulate biometric data specifically. These various privacy and security laws may impact our business activities, including our identification of research subjects, relationships w… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| TCRX-DEBT-12918 | Warrants outstanding: 158071000 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| TCRX-DEBT | Debt stack $32.8M | 90% | Market cache reports total debt of $32.8M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| TCRX-OWNER-LYNX1-CAPITAL-MANAGEMENT-LP | Lynx1 Capital Management LP | 90% | 13F overlay lists Lynx1 Capital Management LP as top holder; 62 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CABA | Cabaletta Bio, Inc. | 100.00 | 2 | |
| ABT | Abbott Laboratories | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| ELVN | Enliven Therapeutics, Inc. | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 1 | ['supplier'] |
| SLGL | Sol-Gel Technologies Ltd. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BNTC | Benitec Biopharma Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | ['supplier'] |
| ATYR | aTyr Pharma, Inc. | 100.00 | 2 |